In prostate cancer, the AKT survival pathway was downregulated by treatment with the LXR agonist T0901317, thereby inducing the apoptotic of LNCaP PCa cells in xenograft nude mice and cell cultures (Pommier et al., 2010). Here, AKT1 is linked to prostate cancer.